Back to search results

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Refractory Melanoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • The University of Alabama at Birmingham, Birmingham, Alabama, United States

    Contact: Study coordinator (Luke Hanna) · lukehanna@uabmc.edu · 205-644-2594
    Contact: Principal Investigator (John Dubay, MD)

  • Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

    Contact: Study coordinator (Mayra Madrid) · Mayra.Madrid2@bannerhealth.com · 480-256-6444
    Contact: Principal Investigator (Fade Mahmoud, MD)

  • Arizona State University-Honor Health Research Institute, Scottsdale, Arizona, United States

    Contact: Study coordinator (Ashley Allison) · aallison@honorhealth.com · 4803231350
    Contact: Principal Investigator (Justin Moser, MD)

  • City of Hope, Duarte, California, United States

    Contact: Study coordinator (Doni Woo) · dwoo@coh.org · 626-218-1970
    Contact: Principal Investigator (Yan Xing, MD, PhD)

  • Massachusetts General Hospital Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Kathryn Cioffi) · kcioffi@mgh.harvard.edu · 866-493-1612
    Contact: Principal Investigator (Alexandra Haugh, MD, MPH)

  • University of North Carolina, Chapel Hill, North Carolina, United States

    Contact: Study coordinator (Claire Kowalczyk) · claire_kowalczyk@med.unc.edu · 919-962-7337
    Contact: Principal Investigator (Stergios Moschos, MD)

  • UT Southwestern, Dallas, Texas, United States

    Contact: Study coordinator (Desiree Pierre) · Desiree.Pierre@utsouthwestern.edu · 214-645-9830
    Contact: Principal Investigator (Sanjay Chandrasekaran, MD)
View source on ClinicalTrials.gov(opens in a new tab)